What is CDMO?

In the context of the PharmaTek platform, users can search for CDMOs based on their specific capabilities, regulatory history, and verified facility data.

A CDMO combines two functions that were historically separate: drug development (process development, formulation, analytical method development, and scale-up) and manufacturing (clinical and commercial supply). That end-to-end scope lets a sponsor hand over a molecule and a target product profile and receive finished, release-tested drug product — without building the facilities, equipment, or specialist headcount in-house.

Services typically span pre-formulation and formulation development, analytical and stability testing, clinical-trial material supply, regulatory and CMC support, scale-up and process validation, and commercial manufacturing across dosage forms — oral solids, sterile injectables, biologics, and high-potency or specialized modalities such as antibody-drug conjugates.

The three acronyms are often used interchangeably but describe different scopes. A CMO (Contract Manufacturing Organization) provides manufacturing capacity against a sponsor's existing, validated process — capacity, not development. A CRO (Contract Research Organization) provides research and clinical-trial services, not manufacturing. A CDMO sits across both: it can develop the process and then manufacture it at clinical and commercial scale.

In practice the lines blur — many CMOs have added development services and now market themselves as CDMOs. When sourcing, look at the actual capability and regulatory record behind the label rather than the acronym a company uses for itself.

Outsourcing to a CDMO avoids the capital cost and lead time of building and validating a facility, gives access to specialized capability (sterile fill-finish, biologics, high-potency containment) without a permanent fixed cost, and lets internal teams stay focused on discovery and clinical strategy. For many small and mid-size biotechs, a CDMO is the only realistic route to clinical and commercial supply.

The trade-off is dependency: every CDMO relationship carries technology-transfer risk and concentration risk. That is why sourcing teams weigh end-to-end CDMOs (fewer transfers) against specialized vendors, and increasingly qualify a second source for critical supply.

A rigorous CDMO selection looks beyond a capability brochure. The core checks are capability and dosage-form fit, available capacity and lead time, quality systems and GMP status, and — critically — regulatory track record. An open FDA Warning Letter, a pattern of Form 483 observations, or repeated Class I/II recalls at a candidate site are material sourcing risks that a capability deck will not show.

Sourcing teams typically run a structured RFI across a shortlist, compare responses side by side, and fold live compliance signals into the decision before committing to diligence or a quality audit. PharmaTek's directory screens CDMOs against FDA recalls, Warning Letters, and Form 483 observations so those risks surface before you engage.